Shares of 60 Degrees Pharmaceuticals Inc (NASDAQ:SXTP) fell about 16.9% in premarket trading on Monday after the company announced a new partnership with GoodRx (NASDAQ:GDRX) aimed at expanding access to its malaria prevention treatment, ARAKODA.
The deal will allow eligible consumers to receive discounts of up to 30% on ARAKODA (tafenoquine), which is currently the only FDA-approved, once-weekly prescription medication for malaria prevention available in the United States. Through GoodRx’s network, patients will be able to obtain the drug at more than 70,000 pharmacies nationwide starting February 2, 2026, or opt for home delivery where available.
ARAKODA is primarily prescribed to travelers visiting malaria-endemic regions. The therapy was developed by the Walter Reed Army Institute of Research and received FDA approval in 2018. Its long terminal half-life of roughly 16 days enables less frequent dosing compared with other prophylactic malaria treatments.
The standard dosing schedule involves an initial loading phase of two 100 mg tablets taken daily for three days prior to travel, followed by a maintenance dose of two 100 mg tablets once weekly during travel for up to six months, and a final two-tablet dose in the week after returning.
Despite the potential for broader patient access through the GoodRx platform, the market reacted negatively to the announcement, with investors pushing the stock sharply lower in early trading.